Peak Processing Limited
Peak Processing Limited
Your view on PKP.AX
Overview
What the company does, where it operates, and who runs it.
About Peak Processing Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Barry Katzman
- Headquarters
- 180 Lonsdale Street, Melbourne, VIC, AU
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Barry Katzman
- Headquarters
- 180 Lonsdale Street, Melbourne, VIC, AU
Based in Melbourne, Australia, and founded in 2016, Peak Processing Limited, alongside its subsidiaries, is engaged in the manufacturing, distribution, and sale of recreational cannabis products throughout Canada and the United States.
Its extensive product line, available through retail outlets, features items such as beverages, hydrocarbon extracts, various oils, vapes, topicals, powders, infused flowers, and edibles.
Furthermore, the company provides a suite of services, including market analysis, product development, production, commercialization strategies, logistical distribution, and product refurbishment.
Notably, the firm was previously known as Althea Group Holdings Limited and is slated to officially change its name to Peak Processing Limited in November 2025.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Peak Processing Limited, and the rating behind it. PKP.AX last traded at AUD 0.02; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Peak Processing Limited. Starting points for Peak Processing Limited: EPS -AUD 0.01, beta 1.51 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Peak Processing Limited. Peak Processing Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Peak Processing Limited. Trailing twelve-month EPS for Peak Processing Limited stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Peak Processing Limited. Peak Processing Limited has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peak Processing Limited valued side by side against its closest peers. Peak Processing Limited is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Peak Processing Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Peak Processing Limited executives and directors. Shares of Peak Processing Limited have traded between AUD 0.01 and AUD 0.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Peak Processing Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Peak Processing Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Peak Processing Limited. Coverage tracks Peak Processing Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.